CAS: 143322-58-1; Eletriptan

该化合物是一种选择性的血清素受体激动剂,主要针对5-HT1B和5-HT1D受体,用于急性治疗偏头痛,口服生物利用率高和快速吸收有助于快速行动,通常在两小时内提供缓解.Eletriptan表现出强烈的受体亲和性,并展示了减少偏头痛症状(包括疼痛,恶心和对照片的恐惧症)的功效.该化合物主要通过CYP3A4 进行肝代谢,需要谨慎小心使用强大的CYP3A4抑制剂.临床研究支持其可耐性,其侧效果与老的三脚塔相比有利.其致癌特性使它成为需要快速有效脊髓灰质减压的病人的可靠选择.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号1225327-17-2 (R)-benzyl 2-(5... | CAS号1162655-06-2 3-[[(R)-1-methy... | CAS号180637-89-2 (R)-3-[(1-甲基-2-... | CAS号75-75-2 甲基磺酸 | CAS号5535-48-8 苯基乙烯基砜 | CAS号10075-50-0 5-溴吲哚 | CAS号143322-57-0 (R)-5-溴-3-(1-甲基... | CAS号1225327-16-1 5-(2-(phenylsul... | CAS号177834-92-3 依来曲普坦氢溴酸盐

合成工艺路线路线简述

  • 合成目标产物 Eletriptan 主要起始原料 2-Chloroethyl Phenyl Sulfone And (R)-N-Acetyl-5-Bromo-3-(N-Methylpyrrolidin-2-Ylmethyl)-1H-Indole
  • (文献来源)合成步骤主要原料 2-Chloroethyl Phenyl Sulfone 和 (R)-N-Acetyl-5-Bromo-3-(N-Methylpyrrolidin-2-Ylmethyl)-1H-Indole
(E)-5-(2-(Phenylsulfonyl)Vinyl)-1H-Indole置于palladium 10% On Activated Carbon Lithium Aluminium Tetrahydride,甲烷磺酸,乙基溴化镁,氢气体系中,用 四氢呋喃,甲醇,乙醚,二氯甲烷,丙酮 用作溶剂,-25.0~5.0 °C,344.75 Kpa 条件下,反应 10.5H,反应生成依来曲普坦
参考文献:Novel Process For The Preparation Of Eletriptan
标题:Novel Process For The Preparation Of Eletriptan
摘要:这项发明涉及一种新型制备(R)-3-((1-甲基吡咯烷-2-基)甲基)-5-(2-(苯磺酰基)乙基)-1H-吲哚及其中间体的方法.

海关参考信息

专利信息


专利号:US-8426612-B2
优先权日:2009-04-22
标 题:Synthesis of 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5[2-(phenylsulfonyl)ethyl]-1H-indole
发明人:SERAFINI SIRO; CASTELLIN ANDREA; DAL SANTO CLAUDIO
权利人:SERAFINI SIRO; CASTELLIN ANDREA; DAL SANTO CLAUDIO; ITALIANA SINT SPA
摘要:The present invention refers to the synthesis of 3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-5-[2-(phenylsulfonyl)ethyl]-1H-indole, a drug known by the name Eletriptan, or of its salts. In particular, the present invention regards a process for the synthesis of Eletriptan or of its salt, comprising the following steps: a) Salifying the intermediate of Formula (6), using a dicarboxylic acid to obtain a derived salt; b) Optionally, purifying said raw salt obtained according to step a) by solvent crystallization to obtain a purified salt of the intermediate of Formula (6); c) Converting said salt of the intermediate of formula (6) according to step a) or said purified salt according to step b) into an intermediate of formula (10); d) Converting the intermediate of Formula (10) into Eletriptan or its salt.

专利号:US-10173993-B2
优先权日:2015-12-09
标题 :Process for the synthesis of sulfones and sulfonamides
发明人:VON WOLFF NIKLAS; CHAR JOËLLE; CANTAT THIBAULT
权利人:COMMISSARIAT ENERGIE ATOMIQUE
摘要:A one pot single step process is described for the synthesis of a compound, including a labeled compound, containing a sulfonyl functional group comprising the step of mixing together a silane, an SO 2 source, an electrophilic compound, an activating compound and optionally a metal catalyst. A process for producing tracers from a labeled sulfonyl containing compound prepared by the described process is also included.

专利号:WO-2005103035-A1
优先权日:2004-04-23
标题:Modified fischer indole synthesis of eletriptan
发明人:ASHCROFT CHRISTOPHER PAUL
权利人:PFIZER LTD; ASHCROFT CHRISTOPHER PAUL; PFIZER
摘要:The present invention relates to a new process for the preparation of eletriptan (I), or its enantiomer comprising a modified Fischer indole synthesis, namely the reaction of a compound of formula (II), wherein R1 is a suitable hydrazine protecting group, with a compound of formula (III) wherein R2 is an aldehyde group (-CHO) or the functional equivalent thereof.

专利号:US-11897827-B1
优先权日:2022-11-22
标 题 :Carbon isotope exchange mediated by vanadium complexes
发明人:BUKHRYAKOV KONSTANTIN
权利人:BUKHRYAKOV KONSTANTIN; THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES
摘要:The subject invention provides catalytical compounds/complexes, compositions comprising such compound/complex, synthesis of the compounds/complexes, and methods of using such compounds/complexes as catalysts in, for example, carbon isotope exchange (CIE) on target bioactive molecules. Methods that allow CIE directly on drug candidates are of great importance to chemistry, biology, and medicine. Especially valuable are catalytic procedures that rely on a limited collection of available labeled materials. The instant method comprises converting a methyl group to terminal â•?CH2 utilizing transfer dehydrogenation catalysts to enable V-based olefin metathesis, followed by a hydrogenation step. The one-pot strategy allows the formal methylation/demethylation sequence and can be applied to an assortment of alkyl-containing compounds.

专利号:WO-2012004811-A8
优先权日:2010-07-06
标题:Process for the preparation of 5-substsituted indole derivative
发明人:BHIRUD SHEKHAR BHASKAR; JOHAR PERMINDER SINGH; SHARMA EKTA; PRAJAPATY RAMKARAN; GUPTA CHANDAN KUMAR
权利人:IND SWIFT LAB LTD; BHIRUD SHEKHAR BHASKAR; JOHAR PERMINDER SINGH; SHARMA EKTA; PRAJAPATY RAMKARAN; GUPTA CHANDAN KUMAR
摘要:The present invention relates to an improved and industrially advantageous process for preparation of eletriptan of formula I, or pharmaceutically acceptable salts thereof from bromo indole intermediate of formula II, through isolation of N-acetylated bromo indole intermediate of formula III, to elude carrying forward of impurities to next stage. The present invention relates to process for the preparation of 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indol of formula II, a key intermediate for the synthesis of eletriptan or pharmaceutically acceptable salts thereof, through novel keto carbamate intermediate. The present invention also relates to novel process for the preparation of α-form of eletriptan hydrobromide.

专利号:WO-2015071831-A1
优先权日:2013-11-18
标 题 :An improved process for minimising the formation of dehalogenated byproducts
发明人:KADAM SHASHIKANT; ARADDY RAJSHEKAR; KONDRAGUNTA VENKATESWARA RAO; HULAVALE YOGESH; SOMISETTI NARENDER RAO; CHENNAMSETTY SUNEEL MANOHAR BABU; HARIHARAN SIVARAMAKRISHNAN
权利人:PIRAMAL ENTPR LTD
摘要:The present invention provides an improved process for preparation of organic compounds represented by Formula-Z; wherein effectively minimising the formation of dehalogenated by-products is achieved. In the process, the reduction is carried out using suitable reducing agent; more preferably Lithium Aluminium Hydride (LAH) in a solvent system, wherein at least one of the solvent is selected from halogenated solvents, which acts as co-solvent. The process of the present invention is useful for minimising of the formation of dehalogenated by-products during synthesis of various active pharmaceutical ingredients such as Paroxetine Hydrochloride, Cinacalcet, Eletriptan and Asenapine.
广州合诚实业有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.honsea.com
电话: 020-38870989👤
📞广州合诚实业有限公司 ⚠️参考联系方式

销售电话:020-38870989
邮箱:gzhs999@163.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:黄埔区萝岗区云埔工业区云城路8号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州开创生物医药有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.creatingbiopharm.com
企业联系电话:0576-88827176;18906581668👤
📞台州开创生物医药有限公司 ⚠️参考联系方式
联系人:余美平
电话:0576-88827176;18906581668
手机:13586099526;18906581668
传真:0576-88822496
邮箱:sales@creatingbiopharm.com
通信地址: 浙江省台州市君悦大厦A幢715
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:浙江省台州市君悦大厦A幢715
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Shelke S, Shahi S, Jadhav K, Dhamecha D, Tiwari R, Patil H. Thermoreversible nanoethosomal gel for the intranasal delivery of Eletriptan hydrobromide. J Mater Sci Mater Med. 2016 Jun;27(6):103. doi: 10.1007/s10856-016-5713-6. Epub 2016 Apr 18. doi: 10.2147/IJGM.S73673. eCollection 2015. Review.
3: Kertesz DP, Trabekin O, Vanetik MS. Headache treatment after electroconvulsive treatment: a single-blinded trial comparator between eletriptan and paracetamol. J ECT. 2015 Jun;31(2):105-9. doi: 10.1097/YCT.0000000000000179. e1-3. doi: 10.1016/j.repc.2014.03.005. Epub 2014 Aug 23. English, Portuguese. doi: 10.1177/0333102413512035. Epub 2013 Nov 21. doi: 10.1111/head.12257. Epub 2013 Oct 29. doi: 10.1177/0333102413500726. Epub 2013 Aug 14. Epub 2012 Aug 30.
9: Yilmaz H, Kaya M, Ozbek M, Delibasi T. A case of hyperprolactinemia, probably induced by eletriptan. Int J Clin Pharmacol Ther. 2012 Dec;50(12):907-8. doi: 10.5414/CP201744. doi: 10.1007/s00216-011-5341-4. Epub 2011 Sep 3. doi: 10.1111/j.1526-4610.2010.01628.x. Epub 2010 Mar 2. pii: CD008490.

合成参考文献


参考文献:10.2165/11590370-000000000-00000
摘要:Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 2011 Aug 01;34(8):691–703. doi: 10.2165/11590370-000000000-00000.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知